Figure 4From: MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expressionERα binding to EREs detected in the MUC1 promoter. The EMSA of the complexes (C1, C2 and C3) developed by ERα from T47D nuclear lysate and 32P-labeled oligonucleotides containing the MUC1 promoter EREs (for details see "Materials and Methods"). A: Binding of ERα to 32P-labeled oligonucleotides ERE1, ERE2, ERE3, ERE4 and ERE5, containing 1/2 consensus core sequence of the classical ERE, and to palindrome like ERE (putative ERE-6 and Vit ERE). Lanes 1, 3, 5, 7, 10, 12, 19 and 26 – complexes developed in absence of anti-ERα Ab; lanes 2, 4, 6, 8, 11, 13, 20 and 27 – partial or complete inhibition of complex formation by anti-ERα Ab; lanes 14, 21 and 28 – binding of ERα to 32P-ERE2, Vit-ERE and ERE6, respectively, in the presence of "cold" Oct1 oligonucleotide; lanes 15–18 – binding of ERα to 32P-ERE2 in presence of decreasing amount of the "cold" ERE2; lanes 22–25 – binding of ERα to 32P-Vit ERE in presence of decreasing amount of the "cold" Vit ERE (* indicates an intermediate complex developed when binding reaction was kept on ice); lanes 29–32 – binding of ERα to 32P-ERE6 in presence of decreasing amount of the "cold" ERE6. B: Effects of anti-ERα Ab and normal rabbit serum (NRS) on ERα binding to MUC1 specific and mutated EREs. Lanes 1, 6 and 11 – binding of ERα in absence of anti-ERα Ab; lanes 2, 7 and 12 – partial or complete inhibition of binding complexes by anti-ERα Ab; lanes 3, 8 and 13 – binding of ERα in presence of NRS; lanes 4, 9 and 14 – binding of ERα to mutated ERE in absence of anti-ERα Ab; lanes 5, 10 and 15 – binding of ERα to mutated ERE in presence of anti-ERα Ab.Back to article page